Exagen Inc. Announces Select Preliminary Full-Year 2023 Results; Cash Balance Of $36.5M As Of December 31, 2023; Reaffirms FY23 Revenue Guidance Of At Least $50M Vs $50.43M Est.
Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year